vs
Acadia Healthcare Company, Inc.（ACHC）与Veralto（VLTO）财务数据对比。点击上方公司名可切换其他公司
Veralto的季度营收约是Acadia Healthcare Company, Inc.的1.7倍（$1.4B vs $821.5M），Veralto净利率更高（17.9% vs -143.3%，领先161.2%），Veralto同比增速更快（6.8% vs 6.1%），Veralto自由现金流更多（$170.0M vs $-179.5M），过去两年Veralto的营收复合增速更高（6.8% vs 3.4%）
阿卡迪亚医疗公司是美国的营利性行为医疗健康服务提供商，目前在美国及波多黎各地区运营着超过225家医疗机构，搭建了覆盖广泛的行为健康服务网络，为有相关需求的人群提供专业的心理健康与行为干预服务。
Veralto是总部位于美国马萨诸塞州沃尔瑟姆的科技企业，核心业务覆盖水分析、水处理、标识喷码、包装及色彩管理相关产品的研发与生产，面向全球多领域客户提供适配的技术产品及配套服务。
ACHC vs VLTO — 直观对比
营收规模更大
VLTO
是对方的1.7倍
$821.5M
营收增速更快
VLTO
高出0.7%
6.1%
净利率更高
VLTO
高出161.2%
-143.3%
自由现金流更多
VLTO
多$349.5M
$-179.5M
两年增速更快
VLTO
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $821.5M | $1.4B |
| 净利润 | $-1.2B | $254.0M |
| 毛利率 | — | 60.1% |
| 营业利润率 | -142.4% | 23.8% |
| 净利率 | -143.3% | 17.9% |
| 营收同比 | 6.1% | 6.8% |
| 净利润同比 | -3710.4% | 12.9% |
| 每股收益（稀释后） | $-12.98 | $1.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACHCVLTO
| Q1 26 | — | $1.4B | ||
| Q4 25 | $821.5M | $1.4B | ||
| Q3 25 | $851.6M | $1.4B | ||
| Q2 25 | $869.2M | $1.3B | ||
| Q1 25 | $770.5M | — | ||
| Q4 24 | $774.2M | $1.3B | ||
| Q3 24 | $815.6M | $1.3B | ||
| Q2 24 | $796.0M | $1.3B |
净利润ACHCVLTO
| Q1 26 | — | $254.0M | ||
| Q4 25 | $-1.2B | $239.0M | ||
| Q3 25 | $36.2M | $222.0M | ||
| Q2 25 | $30.1M | $225.0M | ||
| Q1 25 | $8.4M | — | ||
| Q4 24 | $32.6M | $227.0M | ||
| Q3 24 | $68.1M | $219.0M | ||
| Q2 24 | $78.5M | $203.0M |
毛利率ACHCVLTO
| Q1 26 | — | 60.1% | ||
| Q4 25 | — | 60.1% | ||
| Q3 25 | — | 60.0% | ||
| Q2 25 | — | 60.4% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 59.6% | ||
| Q3 24 | — | 59.6% | ||
| Q2 24 | — | 60.1% |
营业利润率ACHCVLTO
| Q1 26 | — | 23.8% | ||
| Q4 25 | -142.4% | 23.2% | ||
| Q3 25 | 4.7% | 22.8% | ||
| Q2 25 | 5.8% | 24.2% | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 4.9% | 22.9% | ||
| Q3 24 | 12.1% | 23.4% | ||
| Q2 24 | 13.4% | 23.2% |
净利率ACHCVLTO
| Q1 26 | — | 17.9% | ||
| Q4 25 | -143.3% | 17.0% | ||
| Q3 25 | 4.3% | 16.2% | ||
| Q2 25 | 3.5% | 16.9% | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 4.2% | 16.9% | ||
| Q3 24 | 8.4% | 16.7% | ||
| Q2 24 | 9.9% | 15.8% |
每股收益（稀释后）ACHCVLTO
| Q1 26 | — | $1.02 | ||
| Q4 25 | $-12.98 | $0.95 | ||
| Q3 25 | $0.40 | $0.89 | ||
| Q2 25 | $0.33 | $0.90 | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $0.36 | $0.91 | ||
| Q3 24 | $0.74 | $0.88 | ||
| Q2 24 | $0.85 | $0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $133.2M | — |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $1.9B | — |
| 总资产 | $5.5B | — |
| 负债/权益比越低杠杆越低 | 1.28× | — |
8季度趋势，按日历期对齐
现金及短期投资ACHCVLTO
| Q1 26 | — | — | ||
| Q4 25 | $133.2M | $1.8B | ||
| Q3 25 | $118.7M | $1.6B | ||
| Q2 25 | $131.4M | $1.2B | ||
| Q1 25 | $91.2M | — | ||
| Q4 24 | $76.3M | $1.1B | ||
| Q3 24 | $82.1M | $1.3B | ||
| Q2 24 | $77.2M | $1.0B |
总债务ACHCVLTO
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $2.7B | ||
| Q3 25 | $2.3B | $2.7B | ||
| Q2 25 | $2.3B | $2.6B | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.0B | $2.6B | ||
| Q3 24 | $1.9B | $2.6B | ||
| Q2 24 | $1.8B | $2.6B |
股东权益ACHCVLTO
| Q1 26 | — | — | ||
| Q4 25 | $1.9B | $2.8B | ||
| Q3 25 | $3.1B | $2.7B | ||
| Q2 25 | $3.1B | $2.3B | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $3.1B | $2.0B | ||
| Q3 24 | $3.0B | $2.0B | ||
| Q2 24 | $3.0B | $1.7B |
总资产ACHCVLTO
| Q1 26 | — | — | ||
| Q4 25 | $5.5B | $7.4B | ||
| Q3 25 | $6.4B | $7.2B | ||
| Q2 25 | $6.3B | $6.6B | ||
| Q1 25 | $6.1B | — | ||
| Q4 24 | $6.0B | $6.4B | ||
| Q3 24 | $5.9B | $6.3B | ||
| Q2 24 | $5.7B | $5.9B |
负债/权益比ACHCVLTO
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 0.94× | ||
| Q3 25 | 0.74× | 1.01× | ||
| Q2 25 | 0.74× | 1.14× | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.64× | 1.28× | ||
| Q3 24 | 0.62× | 1.35× | ||
| Q2 24 | 0.62× | 1.57× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-86.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-179.5M | $170.0M |
| 自由现金流率自由现金流/营收 | -21.8% | 12.0% |
| 资本支出强度资本支出/营收 | 11.3% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 0.72× |
| 过去12个月自由现金流最近4个季度 | $-439.9M | $893.0M |
8季度趋势，按日历期对齐
经营现金流ACHCVLTO
| Q1 26 | — | $182.0M | ||
| Q4 25 | $-86.3M | $270.0M | ||
| Q3 25 | $73.2M | $339.0M | ||
| Q2 25 | $133.5M | $157.0M | ||
| Q1 25 | $11.5M | — | ||
| Q4 24 | $116.7M | $285.0M | ||
| Q3 24 | $163.1M | $224.0M | ||
| Q2 24 | $171.1M | $251.0M |
自由现金流ACHCVLTO
| Q1 26 | — | $170.0M | ||
| Q4 25 | $-179.5M | $258.0M | ||
| Q3 25 | $-63.0M | $323.0M | ||
| Q2 25 | $-34.2M | $142.0M | ||
| Q1 25 | $-163.2M | — | ||
| Q4 24 | $-86.8M | $263.0M | ||
| Q3 24 | $-27.1M | $215.0M | ||
| Q2 24 | $16.9M | $240.0M |
自由现金流率ACHCVLTO
| Q1 26 | — | 12.0% | ||
| Q4 25 | -21.8% | 18.4% | ||
| Q3 25 | -7.4% | 23.6% | ||
| Q2 25 | -3.9% | 10.7% | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | -11.2% | 19.6% | ||
| Q3 24 | -3.3% | 16.4% | ||
| Q2 24 | 2.1% | 18.6% |
资本支出强度ACHCVLTO
| Q1 26 | — | 0.8% | ||
| Q4 25 | 11.3% | 0.9% | ||
| Q3 25 | 16.0% | 1.2% | ||
| Q2 25 | 19.3% | 1.1% | ||
| Q1 25 | 22.7% | — | ||
| Q4 24 | 26.3% | 1.6% | ||
| Q3 24 | 23.3% | 0.7% | ||
| Q2 24 | 19.4% | 0.9% |
现金转化率ACHCVLTO
| Q1 26 | — | 0.72× | ||
| Q4 25 | — | 1.13× | ||
| Q3 25 | 2.02× | 1.53× | ||
| Q2 25 | 4.43× | 0.70× | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 3.58× | 1.26× | ||
| Q3 24 | 2.39× | 1.02× | ||
| Q2 24 | 2.18× | 1.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACHC
| Acute Inpatient Psychiatric Facilities | $451.2M | 55% |
| Comprehensive Treatment Centers | $144.2M | 18% |
| Medicare | $113.7M | 14% |
| Residential Treatment Centers | $89.7M | 11% |
| Self Payor | $16.1M | 2% |
| Other Payor | $10.7M | 1% |
VLTO
暂无分部数据
